Seeing Is Believing
Currently out of the existing stock ratings of Dane Leone, 104 are a BUY (83.2%), 19 are a HOLD (15.2%), 2 are a SELL (1.6%).
Analyst Dane Leone, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 53.84% that have a potential upside of 28.73% achieved within 197 days.
Dane Leone’s has documented 219 price targets and ratings displayed on 32 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on XLO, Xilio Development at 08-Nov-2024.
Analyst best performing recommendations are on BBIO (BRIDGEBIO PHARMA).
The best stock recommendation documented was for BBIO (BRIDGEBIO PHARMA) at 12/28/2021. The price target of $17 was fulfilled within 6 days with a profit of $3.57 (26.58%) receiving and performance score of 44.3.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
16 days ago
(22-Sep-2025)
0/4 (0%)
$23.75 (380.00%)
Buy
1 months 26 days ago
(12-Aug-2025)
3/4 (75%)
$30.52 (321.94%)
884
Buy
$12
$6.61 (122.63%)
$16
3 months 14 days ago
(24-Jun-2025)
1/4 (25%)
$9.42 (365.12%)
292
Hold
$4
$-1.39 (-25.79%)
$5
4 months 24 days ago
(14-May-2025)
3/5 (60%)
$1.95 (95.12%)
127
Buy
$6
$4.05 (207.69%)
$4
2 years 1 months 3 days ago
(05-Sep-2023)
4/7 (57.14%)
$4.22 (237.08%)
196
What Year was the first public recommendation made by Dane Leone?